Developments in Scanning Electron Microscopy for Tablet and Granule Characterization - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Developments in Scanning Electron Microscopy for Tablet and Granule Characterization
Recent advances in SEM, particularly the incorporation of automation and software, have made simpler, lower-end SEM instruments easy to operate and have improved the capabilities of larger, sophisticated instruments.


Pharmaceutical Technology



FEI COMPANY
Scanning electron microscopy (SEM) provides a qualitative assessment of size, shape, morphology, porosity, size distribution, crystal form, and consistency of powders or compressed dosage forms (see Figure 1). This information can be correlated to assess dissolution behavior, bioavailability, and crystalline structure. SEM images also help analysts determine whether particles are maintaining desired physical characteristics during processing, including after compaction or direct compression (see Figures 2, 3).


Figure 1: (FIGURE COURTESY OF FEI COMPANY)
As an analytical tool, electron microscopy in general has changed extensively, especially with the incorporation of automation and software. An SEM instrument in the 1940s, for example, had a resolving power of about 50 nm and a magnification of 8000. Today, SEM devices have resolving power of 1 nm and a magnification as high as 400,000 (1). Simple, low-end SEM instruments now have touchscreen user interfaces and provide a fast visual inspection of samples. On the very high end, transmission electron microscopes have recently demonstrated the capability to identify individual atoms (2).


Microscopy advances
"Commonly called the laboratory 'workhorse,' microscopes have come a long way to the present day in terms of advancements in automation, higher precision, and better resolution," says Sharon Mathews, a research associate for Technical Insights at Frost & Sullivan. "With digital imaging gaining momentum in the recent years, microscope manufactures are now designing microscopes with image analysis at the forefront" (see sidebar, "Microscopy advances").






Figure 2: (FIGURE COURTESY OF FEI COMPANY)
Mathews attributes the following factors as primary drivers to increasing use of microscopy:
  • Innovations in digital imaging: "Digital imaging offers numerous capabilities to the microscopy market opportunities in terms of enhanced features to extract information or modify the images captured. The convergence of digital imaging and information technology is enabling microscope manufacturers in tailoring their product offerings to suit the specific requirements."
  • Cost effectiveness and ease of operation: "With the diversity of the end-user and lower cost, the microscopy market is steadily growing. Simple automated systems are now increasing the usage of microscopes."
  • Novel applications: "The clinical market, namely, pathology, cytology, and hematology have greatly relied on microscopy over the years. Owing to new imaging applications and research funding, the pharmaceutical, academic, and government laboratories are now propelling the microscopy market. Live cell imaging, molecular imaging enabling identification of events at molecular level and specific applications such as dynamic behavior of cells ... has been responsible for the rapid progress of the microscopy market" (3).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here